02:13 AM EDT, 09/08/2026 (MT Newswires) -- Transgene (TNG.PA) expanded its existing partnership with ProBioGen through an additional license agreement to use the latter's AGE1.CR.pIX suspension cell line. The biotechnology company said Tuesday that the expanded agreement for ProBioGen's specialized production technology will strengthen its manufacturing capabilities and help prepare for future clinical needs at scale.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.